COMP and rheumatoid arthritis: The authors demonstrated that the adalimumab-therapy-triggered decrease in serum COMP levels was more significant in the patients with radiological progression as determined through radiographs of the hands and foot joints than those with a stable radiological course, suggesting that COMP levels may also predict small joint damage in RA [38].